Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1421.09 KRW | -1465.51% |
| 2022 | 104.07 KRW | 85.91% |
| 2021 | 55.98 KRW | -57.17% |
| 2020 | 130.70 KRW | 797.81% |
| 2019 | -18.73 KRW | -133.25% |
| 2018 | -8.03 KRW | 94.03% |
| 2017 | -134.55 KRW | -318.77% |
| 2016 | -32.13 KRW | -237.13% |
| 2015 | 23.43 KRW | 162.5% |
| 2014 | -37.49 KRW | 83.43% |
| 2013 | -226.25 KRW | 26.84% |
| 2012 | -309.25 KRW | -233.24% |
| 2011 | -92.80 KRW | -413.56% |
| 2010 | -18.07 KRW | 97.65% |
| 2009 | -769.46 KRW | -12.65% |
| 2008 | -683.05 KRW | 65.49% |
| 2007 | -1979.10 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -345.65 KRW | -400.36% |
| 2024 Q1 | -69.15 KRW | 93.94% |
| 2023 Q2 | -213.87 KRW | -243.45% |
| 2023 Q3 | -56.16 KRW | 73.74% |
| 2023 Q4 | -1140.51 KRW | -1930.82% |
| 2023 FY | - KRW | -1465.51% |
| 2023 Q1 | 149.09 KRW | 430.87% |
| 2022 FY | - KRW | 85.91% |
| 2022 Q3 | 30.91 KRW | 44.71% |
| 2022 Q4 | -45.06 KRW | -245.78% |
| 2022 Q2 | 21.36 KRW | 9.37% |
| 2022 Q1 | 19.53 KRW | 58.78% |
| 2021 Q1 | 13.44 KRW | 328.96% |
| 2021 Q2 | 11.69 KRW | -13.02% |
| 2021 Q3 | 18.56 KRW | 58.77% |
| 2021 FY | - KRW | -57.17% |
| 2021 Q4 | 12.30 KRW | -33.73% |
| 2020 Q2 | 16.00 KRW | 15.77% |
| 2020 FY | - KRW | 797.81% |
| 2020 Q4 | -5.87 KRW | -118.72% |
| 2020 Q3 | 31.35 KRW | 95.94% |
| 2020 Q1 | 13.82 KRW | 227.37% |
| 2019 Q3 | -8.81 KRW | -171.45% |
| 2019 FY | - KRW | -133.25% |
| 2019 Q2 | 12.33 KRW | 139.19% |
| 2019 Q1 | -31.46 KRW | -17.48% |
| 2019 Q4 | -10.85 KRW | -23.16% |
| 2018 Q3 | 24.77 KRW | 117.66% |
| 2018 FY | - KRW | 94.03% |
| 2018 Q1 | -14.73 KRW | -16.35% |
| 2018 Q2 | 11.38 KRW | 177.26% |
| 2018 Q4 | -26.78 KRW | -208.11% |
| 2017 Q2 | -26.11 KRW | -56.07% |
| 2017 Q3 | -78.99 KRW | -202.53% |
| 2017 FY | - KRW | -318.77% |
| 2017 Q1 | -16.73 KRW | 27.13% |
| 2017 Q4 | -12.66 KRW | 83.97% |
| 2016 FY | - KRW | -237.13% |
| 2016 Q1 | -0.10 KRW | -101.42% |
| 2016 Q4 | -22.96 KRW | -281.4% |
| 2016 Q3 | -6.02 KRW | -349.25% |
| 2016 Q2 | -1.34 KRW | -1240.0% |
| 2015 Q2 | 29.45 KRW | 1207.14% |
| 2015 Q3 | 2.01 KRW | -93.17% |
| 2015 FY | - KRW | 162.5% |
| 2015 Q4 | 7.06 KRW | 251.24% |
| 2015 Q1 | -2.66 KRW | 48.25% |
| 2014 Q2 | -5.53 KRW | 58.7% |
| 2014 Q3 | -13.39 KRW | -142.13% |
| 2014 FY | - KRW | 83.43% |
| 2014 Q1 | -13.39 KRW | 81.64% |
| 2014 Q4 | -5.14 KRW | 61.61% |
| 2013 Q4 | -72.94 KRW | -319.2% |
| 2013 Q3 | -17.40 KRW | 75.01% |
| 2013 FY | - KRW | 26.84% |
| 2013 Q1 | -64.26 KRW | 49.53% |
| 2013 Q2 | -69.62 KRW | -8.34% |
| 2012 Q4 | -127.33 KRW | -1485.68% |
| 2012 Q1 | -33.90 KRW | 0.0% |
| 2012 Q2 | -120.49 KRW | -255.43% |
| 2012 Q3 | -8.03 KRW | 93.34% |
| 2012 FY | - KRW | -233.24% |
| 2011 Q1 | 14.10 KRW | 0.0% |
| 2011 Q2 | 2.14 KRW | -84.82% |
| 2011 Q3 | -39.15 KRW | -1929.44% |
| 2011 FY | - KRW | -413.56% |
| 2011 Q4 | - KRW | 100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 20.08 KRW | 360.55% |
| 2010 FY | - KRW | 97.65% |
| 2010 Q2 | 99.07 KRW | 393.38% |
| 2009 FY | - KRW | -12.65% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 150.29 KRW | 334.02% |
| 2009 Q2 | 113.26 KRW | -24.64% |
| 2009 Q4 | 4.36 KRW | 0.0% |
| 2008 Q4 | -64.22 KRW | 0.0% |
| 2008 Q3 | - KRW | 100.0% |
| 2008 FY | - KRW | 65.49% |
| 2008 Q2 | -274.39 KRW | 72.99% |
| 2008 Q1 | -1015.82 KRW | -1061.73% |
| 2007 Q3 | -1560.98 KRW | -1642.17% |
| 2007 Q2 | -89.60 KRW | 23.26% |
| 2007 Q1 | -116.76 KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | -87.44 KRW | 94.4% |